Evaluate Ltd.: Evaluate Vantage 2021 Preview: High Hopes and Valuations Set the Tone for Biopharma
Evaluate Ltd.: Evaluate Vantage 2021 Preview: High Hopes and Valuations Set the Tone for Biopharma Evaluate Vantage 2021 Preview, published today Sales of COVID-19 vaccines are expected to reach between $10-15bn next year, and for now Moderna's mRNA-1237 is the favored candidate among equity analysts, despite BioNTech and Pfizer's first mover advantage. With many leading COVID-19 projects due to yield data next year, it should become clearer which companies will deliver clinically and commercially successful pandemic products. Across the broader industry, oncology continues to be a major driv...
Source: finanznachrichten.de